These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 39008562)

  • 1. Digital Footprints of Obesity Treatment: GLP-1 Receptor Agonists and the Health Equity Divide.
    Azizi Z; Rodriguez F; Assimes TL
    Circulation; 2024 Jul; 150(3):171-173. PubMed ID: 39008562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of glucagon-like peptide 1 receptor agonists in management of obesity.
    Isaacs D; Prasad-Reddy L; Srivastava SB
    Am J Health Syst Pharm; 2016 Oct; 73(19):1493-507. PubMed ID: 27521241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fair Allocation of GLP-1 and Dual GLP-1-GIP Receptor Agonists.
    Emanuel EJ; Dellgren JL; McCoy MS; Persad G
    N Engl J Med; 2024 May; 390(20):1839-1842. PubMed ID: 38630999
    [No Abstract]   [Full Text] [Related]  

  • 4. Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now?
    Gogineni P; Melson E; Papamargaritis D; Davies M
    Expert Opin Pharmacother; 2024 May; 25(7):801-818. PubMed ID: 38753454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucagon-Like Peptide-1 Based Therapies: A New Horizon in Obesity Management.
    Son JW; Lim S
    Endocrinol Metab (Seoul); 2024 Apr; 39(2):206-221. PubMed ID: 38626909
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists.
    Ard J; Fitch A; Fruh S; Herman L
    Adv Ther; 2021 Jun; 38(6):2821-2839. PubMed ID: 33977495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatohepatitis.
    Abdelmalek MF; Harrison SA; Sanyal AJ
    Diabetes Obes Metab; 2024 Jun; 26(6):2001-2016. PubMed ID: 38511418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucagon-like peptide-1 receptor agonists and cardiovascular disease: from LEADER to EXSCEL.
    Torekov SS
    Cardiovasc Res; 2018 Aug; 114(10):e70-e71. PubMed ID: 30052921
    [No Abstract]   [Full Text] [Related]  

  • 9. [A new era for glucagon-like peptide-1 receptor agonists].
    Neuville MF; Paquot N; Scheen AJ
    Rev Med Liege; 2023 Jan; 78(1):40-45. PubMed ID: 36634066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wegovy (semaglutide): a new weight loss drug for chronic weight management.
    Singh G; Krauthamer M; Bjalme-Evans M
    J Investig Med; 2022 Jan; 70(1):5-13. PubMed ID: 34706925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GLP-1R agonists for the treatment of obesity: a patent review (2015-present).
    Liu C; Zou Y; Qian H
    Expert Opin Ther Pat; 2020 Oct; 30(10):781-794. PubMed ID: 32799587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapies for inter-relating diabetes and obesity - GLP-1 and obesity.
    Iepsen EW; Torekov SS; Holst JJ
    Expert Opin Pharmacother; 2014 Dec; 15(17):2487-500. PubMed ID: 25260877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of lifestyle and glucagon-like peptide-1 receptor agonists for weight loss in obesity, type 2 diabetes and steatotic liver diseases.
    Giannakogeorgou A; Roden M
    Aliment Pharmacol Ther; 2024 Jun; 59 Suppl 1():S52-S75. PubMed ID: 38813830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon-like peptide agonists: A prospective review.
    Mariam Z; Niazi SK
    Endocrinol Diabetes Metab; 2024 Jan; 7(1):e462. PubMed ID: 38093651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GLP-1 Agonists for Obesity-A New Recipe for Success?
    Mozaffarian D
    JAMA; 2024 Mar; 331(12):1007-1008. PubMed ID: 38421659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date.
    Brunton SA; Wysham CH
    Postgrad Med; 2020 Nov; 132(sup2):3-14. PubMed ID: 32815454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease.
    Baggio LL; Drucker DJ
    Mol Metab; 2021 Apr; 46():101090. PubMed ID: 32987188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endogenous glucagon-like peptide (GLP)-1 as alternative for GLP-1 receptor agonists: Could this work and how?
    Smits MM; Holst JJ
    Diabetes Metab Res Rev; 2023 Nov; 39(8):e3699. PubMed ID: 37485788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-sectional, case-control and longitudinal associations between exposure to glucagon-like peptide-1 receptor agonists and the dispensing of antidepressants.
    Almeida OP; Fong Z; Hill Almeida LM; Sanfilippo FM; Page A; Etherton-Beer C
    Diabetes Obes Metab; 2024 Jul; 26(7):2925-2932. PubMed ID: 38650544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity.
    Jepsen MM; Christensen MB
    Expert Opin Emerg Drugs; 2021 Sep; 26(3):231-243. PubMed ID: 34176426
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.